CL2020001800A1 - Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma. - Google Patents

Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma.

Info

Publication number
CL2020001800A1
CL2020001800A1 CL2020001800A CL2020001800A CL2020001800A1 CL 2020001800 A1 CL2020001800 A1 CL 2020001800A1 CL 2020001800 A CL2020001800 A CL 2020001800A CL 2020001800 A CL2020001800 A CL 2020001800A CL 2020001800 A1 CL2020001800 A1 CL 2020001800A1
Authority
CL
Chile
Prior art keywords
ige
probiotics
composition
present
polypeptide
Prior art date
Application number
CL2020001800A
Other languages
English (en)
Inventor
Young Chul Sung
Zungyoon Yang
Myoung Ho Jang
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of CL2020001800A1 publication Critical patent/CL2020001800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición que contiene, como ingredientes activos, probióticos y un polipéptido con capacidad de unión a IgE. En particular, se identificó un efecto sinérgico de disminución notable de la alergia alimentaria en el momento de la administración combinada de probióticos y una proteína recombinante que contiene un dominio extracelular de una subunidad alfa de un receptor Fc de IgE de conformidad con la presente invención. Por lo tanto, se espera que la composición de la presente invención sea altamente aplicable industrialmente debido a que puede presentar un efecto terapéutico notable sobre una enfermedad alérgica mediada por IgE en comparación con las composiciones farmacéuticas convencionales.
CL2020001800A 2018-01-12 2020-07-03 Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma. CL2020001800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180004421 2018-01-12

Publications (1)

Publication Number Publication Date
CL2020001800A1 true CL2020001800A1 (es) 2020-10-30

Family

ID=67218660

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001800A CL2020001800A1 (es) 2018-01-12 2020-07-03 Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma.

Country Status (18)

Country Link
US (1) US12128076B2 (es)
EP (1) EP3738599B1 (es)
JP (1) JP7041272B2 (es)
KR (1) KR102038679B1 (es)
CN (1) CN111587118B (es)
AU (1) AU2019206205B2 (es)
BR (1) BR112020013818A2 (es)
CA (1) CA3086224A1 (es)
CL (1) CL2020001800A1 (es)
ES (1) ES2969110T3 (es)
IL (1) IL275593B (es)
MX (1) MX2020007032A (es)
MY (1) MY205046A (es)
PE (1) PE20210108A1 (es)
PH (1) PH12020551069A1 (es)
SG (1) SG11202005863TA (es)
TW (1) TWI737955B (es)
WO (1) WO2019139434A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135668A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
EP3927375A4 (en) * 2019-02-20 2022-11-23 Siolta Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
KR102561135B1 (ko) 2019-07-08 2023-07-31 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물
WO2022015049A1 (ko) * 2020-07-17 2022-01-20 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도
KR20220011931A (ko) * 2020-07-22 2022-02-03 (주)지아이이노베이션 IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JPH10309178A (ja) 1997-05-09 1998-11-24 Wakamoto Pharmaceut Co Ltd ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品
JP2000095697A (ja) 1998-09-18 2000-04-04 Advance Co Ltd 抗アレルギー剤
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
JP2009067679A (ja) 2005-12-27 2009-04-02 Univ Of Tokushima 抗ヒスタミン作用を有する医薬
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
US20090196921A1 (en) 2008-02-06 2009-08-06 The Procter & Gamble Company Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
BRPI0918670B8 (pt) 2008-09-17 2021-05-25 Xencor Inc anticorpo
KR101832510B1 (ko) 2009-10-26 2018-02-26 제넨테크, 인크. 치료 항-ｉｇｅ 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
KR20120135865A (ko) * 2011-06-07 2012-12-17 (주)네오팜 ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물
CN103169733B (zh) * 2011-12-26 2014-11-12 浙江贝因美科工贸股份有限公司 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
CA2979086A1 (en) * 2015-03-12 2016-09-15 The University Of British Columbia Bacterial compositions and methods of use thereof
KR101778734B1 (ko) 2016-03-11 2017-09-18 대한민국(농촌진흥청장) 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물
WO2019135668A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
TW201930343A (zh) * 2018-01-08 2019-08-01 南韓商普羅根有限公司 包含IgE受體之重組型胞外區域的藥學組成物

Also Published As

Publication number Publication date
WO2019139434A1 (ko) 2019-07-18
KR102038679B1 (ko) 2019-10-30
MY205046A (en) 2024-09-29
SG11202005863TA (en) 2020-07-29
JP2021510689A (ja) 2021-04-30
CA3086224A1 (en) 2019-07-18
CN111587118A (zh) 2020-08-25
EP3738599C0 (en) 2023-12-27
PH12020551069A1 (en) 2021-09-06
KR20190086396A (ko) 2019-07-22
MX2020007032A (es) 2020-12-03
JP7041272B2 (ja) 2022-03-23
IL275593A (en) 2020-08-31
US20220347236A1 (en) 2022-11-03
IL275593B (en) 2022-01-01
RU2020122021A (ru) 2022-02-14
ES2969110T3 (es) 2024-05-16
EP3738599A4 (en) 2021-10-27
AU2019206205A1 (en) 2020-06-25
TW201932129A (zh) 2019-08-16
TWI737955B (zh) 2021-09-01
US12128076B2 (en) 2024-10-29
EP3738599B1 (en) 2023-12-27
PE20210108A1 (es) 2021-01-19
BR112020013818A2 (pt) 2020-12-01
CN111587118B (zh) 2023-11-21
EP3738599A1 (en) 2020-11-18
AU2019206205B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
CL2020001800A1 (es) Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma.
MX2024004936A (es) Variantes de capsides de aav y sus usos.
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
PE20151421A1 (es) Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
MX2017003117A (es) Particula tipo virus de flavivirus.
MX2020007030A (es) Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo.
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CU20210008A7 (es) Aspirasas solubilizadas
MX344183B (es) Proteina antimicrobiana.
MX2021007354A (es) Polipeptidos con actividad fitasica.
EP3811933A4 (en) FREEZE-DRIED PREPARATION OF EXOSOMES DERIVED FROM STEM CELLS AND ANTI-INFLAMMATORY COMPOSITION COMPRISING THEM AS ACTIVE PRINCIPLE
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
MX2024000757A (es) Variantes recombinantes de proteínas r-espondina y uso de las mismas.
BR112018070929A2 (pt) peptídeos bioativos peguilados e seu uso
TH2001005979A (th) การลดความหนืดของสูตรผสมโปรตีนที่มีความเข้มข้นสูง